Although Duchenne Muscular Dystrophy (DMD) is a rare disease, multiple targets are being pursued to find treatments. As a result, DMD patients have several options when considering enrolling in clinical trials, which can contribute to the challenges when recruiting DMD patients for specific clinical trials. Raymond A. Huml et al. of IQVIA present the results of a proactive DMD feasibility study, which was conducted in the second half of 2018, with the objective of obtaining unique and current insights from global investigators currently providing DMD patient care.